Pegylated Liposomal Doxorubicin Hydrochloride With Atezolizumab and/or Bevacizumab in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Purpose
This phase II/III trial studies how well pegylated liposomal doxorubicin hydrochloride with atezolizumab and/or bevacizumab work in treating patients with ovarian, fallopian tube, or primary peritoneal cancer that has come back (recurrent). Chemotherapy drugs, such as pegylated liposomal doxorubicin hydrochloride, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Immunotherapy with monoclonal antibodies, such as atezolizumab and bevacizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. It is not yet known which combination will work better in treating patients with ovarian, fallopian tube, or primary peritoneal cancer.
Conditions
- High Grade Fallopian Tube Serous Adenocarcinoma
- High Grade Ovarian Serous Adenocarcinoma
- Ovarian Seromucinous Carcinoma
- Primary Peritoneal High Grade Serous Adenocarcinoma
- Recurrent Fallopian Tube Carcinoma
- Recurrent Fallopian Tube Clear Cell Adenocarcinoma
- Recurrent Fallopian Tube Endometrioid Adenocarcinoma
- Recurrent Fallopian Tube Undifferentiated Carcinoma
- Recurrent Ovarian Carcinoma
- Recurrent Ovarian Clear Cell Adenocarcinoma
- Recurrent Ovarian Endometrioid Adenocarcinoma
- Recurrent Ovarian Undifferentiated Carcinoma
- Recurrent Platinum-Resistant Fallopian Tube Carcinoma
- Recurrent Platinum-Resistant Ovarian Carcinoma
- Recurrent Platinum-Resistant Primary Peritoneal Carcinoma
- Recurrent Primary Peritoneal Carcinoma
- Recurrent Primary Peritoneal Clear Cell Adenocarcinoma
- Recurrent Primary Peritoneal Endometrioid Adenocarcinoma
- Recurrent Primary Peritoneal Undifferentiated Carcinoma
Eligibility
- Eligible Ages
- Over 18 Years
- Eligible Genders
- Female
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- Patients must have the psychological ability and general health that permits completion of the study requirements and required follow up - Administration of study drugs (pegylated liposomal doxorubicin, bevacizumab, atezolizumab) may have an adverse effect on pregnancy and poses a risk to the human fetus, including embryo-lethality; women of child-bearing potential (WOCBP) must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry, for the duration of study participation, and for 5 months (150 days) after the last dose of study agent; should a woman become pregnant or suspect she is pregnant while she is participating in this study, she should inform her treating physician immediately - Submission of tumor tissue is required for all patients; investigators should check with their site pathology department regarding release of biospecimens before approaching patients about participation in the trial - High grade ovarian cancer, including high grade serous; clear cell; endometrioid, grade 3; and others (adenocarcinoma, not otherwise specified [NOS]; mixed epithelial carcinoma; undifferentiated carcinoma); NOTE: low grade serous, mucinous and carcinosarcoma histologies are excluded due to their different underlying genomic features and/or clinical behavior; ovarian cancer = ovarian, fallopian tube or primary peritoneal cancer; required data element: submission of pathology report - Recurrent, platinum resistant ovarian cancer (defined as progression within < 6 months from completion of platinum based therapy; the date should be calculated from the last administered dose of platinum therapy) - 1-2 prior regimens (including primary therapy); hormonal therapies (e.g., tamoxifen, aromatase inhibitors) will not count toward the prior regimen limit; PARP inhibitors given in the maintenance setting post response to platinum-based therapy will not count as a separate regimen from the preceding platinum-based therapy - Measurable disease (defined by RECIST v1.1) or evaluable disease (defined as solid and/or cystic abnormalities on radiographic imaging that do not meet RECIST 1.1 definitions for target lesions OR ascites and/or pleural effusion that has been pathologically demonstrated to be disease related in the setting of cancer antigen [CA]25 >= 2 x upper limit of normal [ULN]) - Performance status 0, 1 or 2 - Absolute neutrophil count (ANC) >= 1,500/mcl (within 14 days prior to registration) - Platelets >= 100,000/mcl (within 14 days prior to registration) - Hemoglobin (Hgb) >= 8 g/dl (within 14 days prior to registration) - Creatinine =< 1.5 x institutional upper limit of normal (ULN) (within 14 days prior to registration) - Urine protein creatinine (UPC) ratio must be < 1.0 (within 14 days prior to registration); if UPC ratio >= 1, collection of 24-hour urine measurement of urine protein is recommended (24-hour urine protein level must be < 1000 mg for patient enrollment); If UPC ratio cannot be calculated because the urine protein is below the lower limit of detection of the assay this will not exclude the patient; UPC ratio of spot urine is an estimation of the 24-hour urine protein excretion - a UPC ratio of 1 is roughly equivalent to a 24-hour urine protein of 1 gm - Total bilirubin =< 1.5 x ULN (patients with known Gilbert disease who have serum bilirubin level =< 3 x ULN may be enrolled) (within 14 days prior to registration) - Aspartate aminotransferase (AST)/alanine aminotransferase (ALT) =< 3 x ULN (AST and/or ALT =< 5 x ULN for patients with liver involvement) (within 14 days prior to registration) - International normalized ratio (INR) and activated partial thromboplastin time (aPTT) =< 1.5 x ULN (or on stable dose of therapeutic anticoagulation, such as low-molecular-weight heparin, warfarin or rivaroxaban) - Thyroid-stimulating hormone (TSH) within normal limits (Euthyroid patients on thyroid replacement therapy allowed provided TSH < ULN) - The patient or legally authorized representative must provide study-specific informed consent prior to study entry and, for patients treated in the United States (U.S.), authorization permitting release of personal health information
Exclusion Criteria
- Patients with prior allogeneic bone marrow transplantation or prior solid organ transplantation - Patients who have had systemic anticancer therapy (e.g., chemotherapy, targeted therapy including PARP inhibitors or bevacizumab) within 3 weeks prior to entering the study - Patients who have had hormonal therapy (e.g., tamoxifen, aromatase inhibitor) within 1 week prior to entering the study - Patients with prior treatment with anti-programmed cell death (PD)-1, anti- programmed cell death ligand (PD-L)1 or anti-cytotoxic T-lymphocyte-associated protein (CTLA)-4 therapeutic antibody or other similar agents - Patients with prior treatment with bevacizumab (or any other anti vascular therapy, e.g., cediranib) for platinum resistant recurrence; (Note: prior bevacizumab in initial therapy and/or platinum sensitive recurrent setting is allowed) - Patients with prior treatment with PLD - Prior radiotherapy to the abdomen or pelvis - Patients who have not recovered from adverse events to =< grade 1 (other than alopecia) due to agents administered more than 3 weeks earlier; however, the following therapies are allowed: - Hormone replacement therapy or oral contraceptives - Herbal therapy > 1 week prior to cycle 1, day 1 (herbal therapy intended as anticancer therapy must be discontinued at least 1 week prior to cycle 1, day 1) - Palliative radiotherapy for bone metastases > 2 weeks prior to cycle 1, day 1 - Treatment with any other investigational agent within 4 weeks prior to cycle 1, day 1 - Treatment with systemic immunostimulatory agents (including, but not limited to, interferon [IFN]-alpha or interleukin [IL]-2) within 6 weeks prior to cycle 1, day 1 - Treatment with systemic immunosuppressive medications (including, but not limited to, prednisone, cyclophosphamide, azathioprine, methotrexate, thalidomide, and anti-tumor necrosis factor [anti-TNF] agents) within 2 weeks prior to cycle 1, day 1 - Patients who have received acute, low dose, systemic immunosuppressant medications (e.g., a one-time dose of dexamethasone for nausea or steroids as computed tomography [CT] scan contrast premedication) may be enrolled - The use of inhaled corticosteroids and mineralocorticoids (e.g., fludrocortisone) for patients with orthostatic hypotension or adrenocortical insufficiency is allowed - Patients taking bisphosphonate therapy for symptomatic hypercalcemia within the past 28 days; use of bisphosphonate therapy for other reasons (e.g., bone metastasis or osteoporosis) is allowed - Patients with known primary central nervous system (CNS) malignancy or symptomatic CNS metastases are excluded, with the following exceptions: - Patients with asymptomatic untreated CNS disease may be enrolled, provided all of the following criteria are met: - Evaluable or measurable disease outside the CNS - No metastases to brain stem, midbrain, pons, medulla, cerebellum, or within 10 mm of the optic apparatus (optic nerves and chiasm) - No history of intracranial hemorrhage or spinal cord hemorrhage - No ongoing requirement for dexamethasone for CNS disease; patients on a stable dose of anticonvulsants are permitted - No neurosurgical resection or brain biopsy within 28 days prior to cycle 1, day 1 - Patients with asymptomatic treated CNS metastases may be enrolled, provided all the criteria listed above are met as well as the following: - Radiographic demonstration of improvement upon the completion of CNS directed therapy and no evidence of interim progression between the completion of CNS directed therapy and the screening radiographic study - No stereotactic radiation or whole-brain radiation within 28 days prior to cycle 1, day 1 - Screening CNS radiographic study >= 4 weeks from completion of radiotherapy and >= 2 weeks from discontinuation of corticosteroids - Known hypersensitivity to Chinese hamster ovary cell products or other recombinant human antibodies - History of severe allergic, anaphylactic, or other hypersensitivity reactions to chimeric or humanized antibodies or fusion proteins - Patients requiring treatment with a receptor activator of nuclear factor kappa-B ligand (RANKL) inhibitor (e.g. denosumab) who cannot discontinue it before treatment with atezolizumab - Known clinically significant liver disease, including active viral, alcoholic, or other hepatitis; cirrhosis; fatty liver; and inherited liver disease - Patients with past or resolved hepatitis B infection (defined as having a negative hepatitis B surface antigen [HBsAg] test and a positive anti-HBc [antibody to hepatitis B core antigen] antibody test) are eligible - Patients positive for hepatitis C virus (HCV) antibody are eligible only if polymerase chain reaction (PCR) is negative for HCV ribonucleic acid (RNA) - History or risk of autoimmune disease, including but not limited to systemic lupus erythematosus, rheumatoid arthritis, inflammatory bowel disease, vascular thrombosis associated with antiphospholipid syndrome, Wegener's granulomatosis, Sjogren's syndrome, Guillain-Barre syndrome, multiple sclerosis, autoimmune thyroid disease, vasculitis, or glomerulonephritis - Patients with a history of autoimmune hypothyroidism on a stable dose of thyroid replacement hormone are eligible - Patients with controlled type 1 diabetes mellitus on a stable insulin regimen, or type 2 diabetes mellitus are eligible - Patients with eczema, psoriasis, lichen simplex chronicus or vitiligo with dermatologic manifestations only (e.g., patients with psoriatic arthritis would be excluded) are permitted provided that they meet the following conditions: - Patients with psoriasis must have a baseline ophthalmologic exam to rule out ocular manifestations - Rash must cover less than 10% of body surface area (BSA) - Disease is well controlled at baseline and only requiring low potency topical steroids (e.g., hydrocortisone 2.5%, hydrocortisone butyrate 0.1%, fluocinolone 0.01%, desonide 0.05%, alclometasone dipropionate 0.05%) - No acute exacerbations of underlying condition within the last 12 months (not requiring psoralen plus ultraviolet A radiation [PUVA], methotrexate, retinoids, biologic agents, oral calcineurin inhibitors; high potency or oral steroids) - History of idiopathic pulmonary fibrosis, pneumonitis (including drug induced), organizing pneumonia (i.e., bronchiolitis obliterans, cryptogenic organizing pneumonia, etc.), or evidence of active pneumonitis on screening chest computed tomography (CT) scan; history of radiation pneumonitis in the radiation field (fibrosis) is permitted - Patients with active tuberculosis (TB) are excluded - Severe infections within 4 weeks prior to cycle 1, day 1, including but not limited to hospitalization for complications of infection, bacteremia, or severe pneumonia - Signs or symptoms of infection within 2 weeks prior to cycle 1, day 1 - Received oral or intravenous (IV) antibiotics within 2 weeks prior to cycle 1, day 1; patients receiving prophylactic antibiotics (e.g., for prevention of a urinary tract infection or chronic obstructive pulmonary disease) are eligible - Major surgical procedure within 28 days prior to cycle 1, day 1 or anticipation of need for a major surgical procedure during the course of the study - Administration of a live, attenuated vaccine within 4 weeks before cycle 1, day 1 or anticipation that such a live, attenuated vaccine will be required during the study and up to 5 months after the last dose of atezolizumab - Influenza vaccination should be given during influenza season only (approximately October to March); patients must not receive live, attenuated influenza vaccine within 4 weeks prior to cycle 1, day 1 or at any time during the study - Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements - Patients with known human immunodeficiency virus (HIV) are NOT excluded from this study, but HIV-positive patients must have: - A stable regimen of highly active anti-retroviral therapy (HAART) - No requirement for concurrent antibiotics or antifungal agents for the prevention of opportunistic infections - A cluster of differentiation (CD)4 count above 250 cells/mcL and an undetectable HIV viral load on standard PCR-based tests - Prior invasive malignancy (except non-melanomatous skin cancer) unless disease free for a minimum of 3 years, with the exception of those with a negligible risk of metastases or death, such as carcinoma in situ of the breast or cervix - Severe, active co-morbidity defined as follows: - Current (within 28 days of cycle 1, day 1) signs and/or symptoms of bowel obstruction - Patients who require parental hydration and/or nutrition - Patients who require drainage gastrostomy tube - Evidence of bleeding diathesis or clinically significant coagulopathy - Serious, non-healing or dehiscing wound, active ulcer or untreated bone fracture - History of hemoptysis (>= 1/2 teaspoon of bright red blood per episode) within 1 month of study enrollment - Significant cardiovascular or cerebrovascular disease including: - Uncontrolled hypertension (systolic blood pressure [SBP] >= 150 and/or diastolic blood pressure [DBP] >= 90) - History of myocardial infarction within 6 months - Unstable angina - New York Heart Association functional classification II, III or IV - Baseline ejection fraction =< 50% as assessed by echocardiogram or multi-gated acquisition (MUGA) - Cerebral vascular accident (CVA) or transient ischemic attack (TIA) within 6 months - Significant vascular disease (e.g., aortic aneurysm, requiring surgical repair or peripheral arterial thrombosis) within 6 months - History of abdominal/pelvic or tracheoesophageal fistula or gastrointestinal perforation and/or abodiminal/pelvic abscess within 6 months prior to initiation of treatment - Pregnant or lactating patients
Study Design
- Phase
- Phase 2/Phase 3
- Study Type
- Interventional
- Allocation
- Randomized
- Intervention Model
- Parallel Assignment
- Primary Purpose
- Treatment
- Masking
- None (Open Label)
Arm Groups
Arm | Description | Assigned Intervention |
---|---|---|
Experimental Arm I (PLD, atezolizumab) |
Patients receive pegylated liposomal doxorubicin hydrochloride IV over 60 minutes on day 1 and atezolizumab IV over 30-60 minutes on days 1 and 15. |
|
Experimental Arm II (PLD, bevacizumab, atezolizumab) |
Patients receive pegylated liposomal doxorubicin hydrochloride IV over 60 minutes on day 1, bevacizumab IV over 30-90 minutes on days 1 and 15, and atezolizumab IV over 30-60 minutes on days 1 and 15. |
|
Active Comparator Arm III (PLD, bevacizumab) |
Patients receive pegylated liposomal doxorubicin hydrochloride IV over 60 minutes on day 1 and bevacizumab IV over 30-90 minutes on days 1 and 15. |
|
Recruiting Locations
Anchorage, Alaska 98508
Anchorage, Alaska 99504
Anchorage, Alaska 99508
Anchorage, Alaska 99508
Anchorage, Alaska 99508
Anchorage, Alaska 99508
Anchorage, Alaska 99508
Anchorage, Alaska 99508
Fairbanks, Alaska 99701
Kingman, Arizona 86401
Phoenix, Arizona 85004
Site Public Contact
602-406-8222
Tucson, Arizona 85719
Fort Smith, Arkansas 72903
Site Public Contact
800-378-9373
Hot Springs, Arkansas 71913
Little Rock, Arkansas 72205
Site Public Contact
501-686-8274
Anaheim, California 92806
Antioch, California 94531
Arroyo Grande, California 93420
Arroyo Grande, California 93420
Auburn, California 95602
Auburn, California 95603
Baldwin Park, California 91706
Bellflower, California 90706
Berkeley, California 94704
Burbank, California 91505
Cameron Park, California 95682
Carmichael, California 95608
Castro Valley, California 94546
Concord, California 94520
Site Public Contact
925-674-2580
Davis, California 95616
Dublin, California 94568
Site Public Contact
925-875-1677
Dublin, California 94568
Site Public Contact
877-642-4691
Elk Grove, California 95758
Emeryville, California 94608
Site Public Contact
510-835-9900
Emeryville, California 94608
Site Public Contact
510-629-6682
Fontana, California 92335
Fremont, California 94538
Fremont, California 94538
Fresno, California 93720
Fresno, California 93720
Greenbrae, California 94904
Harbor City, California 90710
Irvine, California 92618
Loma Linda, California 92354
Site Public Contact
909-558-4050
Los Angeles, California 90027
Los Angeles, California 90034
Martinez, California 94553-3156
Site Public Contact
925-957-5400
Modesto, California 95355
Modesto, California 95356
Mountain View, California 94040
Mountain View, California 94040
Oakland, California 94609
Site Public Contact
510-204-1414
Oakland, California 94609
Oakland, California 94611
Oakland, California 94611
Ontario, California 91761
Orange, California 92868
Palo Alto, California 94301
Panorama City, California 91402
Rancho Cordova, California 95670
Redwood City, California 94063
Richmond, California 94801
Riverside, California 92505
Rocklin, California 95765
Rohnert Park, California 94928
Roseville, California 95661
Roseville, California 95661
Roseville, California 95661
Roseville, California 95678
Sacramento, California 95814
Sacramento, California 95816
Sacramento, California 95816
Sacramento, California 95823
Sacramento, California 95823
Sacramento, California 95825
San Diego, California 92108
San Diego, California 92120
San Francisco, California 94115
San Francisco, California 94115
San Francisco, California 94158
Site Public Contact
877-827-3222
San Jose, California 95119
San Leandro, California 94577
San Luis Obispo, California 93401
San Marcos, California 92078
San Rafael, California 94903
San Rafael, California 94903
Santa Clara, California 95051
Santa Cruz, California 95065
Santa Maria, California 93444
Santa Rosa, California 95403
Santa Rosa, California 95403
South San Francisco, California 94080
South San Francisco, California 94080
Stockton, California 95210
Sunnyvale, California 94086
Vacaville, California 95687
Vacaville, California 95688
Vallejo, California 94589
Vallejo, California 94589
Walnut Creek, California 94596
Walnut Creek, California 94597
Walnut Creek, California 94598
Site Public Contact
925-941-4246
Woodland Hills, California 91367
Woodland, California 95695
Aurora, Colorado 80012
Aurora, Colorado 80012
Aurora, Colorado 80045
Site Public Contact
720-848-0650
Boulder, Colorado 80304
Centennial, Colorado 80112
Colorado Springs, Colorado 80907
Colorado Springs, Colorado 80907
Denver, Colorado 80204
Site Public Contact
303-777-2663
Denver, Colorado 80205
Denver, Colorado 80206
Denver, Colorado 80209
Denver, Colorado 80210
Denver, Colorado 80218
Denver, Colorado 80218
Denver, Colorado 80218
Denver, Colorado 80218
Denver, Colorado 80220
Denver, Colorado 80220
Site Public Contact
303-777-2663
Durango, Colorado 81301
Durango, Colorado 81301
Englewood, Colorado 80113
Englewood, Colorado 80113
Fort Collins, Colorado 80524
Site Public Contact
970-297-6150
Golden, Colorado 80401
Grand Junction, Colorado 81501
Greeley, Colorado 80631
Lafayette, Colorado 80026
Site Public Contact
303-673-1622
Lafayette, Colorado 80026
Lakewood, Colorado 80228
Littleton, Colorado 80120
Littleton, Colorado 80122
Lone Tree, Colorado 80124
Lone Tree, Colorado 80124
Lone Tree, Colorado 80124
Longmont, Colorado 80501
Longmont, Colorado 80501
Loveland, Colorado 80539
Parker, Colorado 80138
Pueblo, Colorado 81004
Thornton, Colorado 80260
Danbury, Connecticut 06810
Site Public Contact
203-739-8074
Hartford, Connecticut 06102
Site Public Contact
860-545-5363
New Britain, Connecticut 06050
Site Public Contact
860-224-5660
Norwalk, Connecticut 06856
Frankford, Delaware 19945
Lewes, Delaware 19958
Newark, Delaware 19713
Newark, Delaware 19713
Newark, Delaware 19713
Newark, Delaware 19718
Rehoboth Beach, Delaware 19971
Seaford, Delaware 19973
Wilmington, Delaware 19801
Washington, District of Columbia 20002
Site Public Contact
301-548-5743
Washington, District of Columbia 20016
Aventura, Florida 33180
Miami Beach, Florida 33140
Atlanta, Georgia 30308
Site Public Contact
888-946-7447
Atlanta, Georgia 30322
Site Public Contact
404-778-1868
Atlanta, Georgia 30342
Site Public Contact
404-851-7115
Atlanta, Georgia 30342
Augusta, Georgia 30912
Gainesville, Georgia 30501
Savannah, Georgia 31404
Savannah, Georgia 31404
Savannah, Georgia 31405
Savannah, Georgia 31405
'Aiea, Hawaii 96701
Site Public Contact
808-539-2273
'Aiea, Hawaii 96701
Site Public Contact
808-486-6000
'Aiea, Hawaii 96701
Site Public Contact
808-487-7447
'Aiea, Hawaii 96701
Site Public Contact
808-678-9000
Honolulu, Hawaii 96813
Honolulu, Hawaii 96813
Honolulu, Hawaii 96813
Site Public Contact
808-532-0315
Honolulu, Hawaii 96813
Site Public Contact
808-545-8548
Honolulu, Hawaii 96813
Site Public Contact
808-522-4333
Honolulu, Hawaii 96813
Site Public Contact
808-586-2979
Honolulu, Hawaii 96817
Site Public Contact
808-536-4888
Honolulu, Hawaii 96817
Site Public Contact
808-547-9816
Honolulu, Hawaii 96817
Site Public Contact
808-531-8521
Honolulu, Hawaii 96817
Site Public Contact
808-547-6881
Honolulu, Hawaii 96819
Honolulu, Hawaii 96826
Site Public Contact
808-983-6090
Lihue, Hawaii 96766
Site Public Contact
808-535-7960
Boise, Idaho 83706
Boise, Idaho 83712
Caldwell, Idaho 83605
Coeur d'Alene, Idaho 83814
Emmett, Idaho 83617
Fruitland, Idaho 83619
Meridian, Idaho 83642
Meridian, Idaho 83642
Nampa, Idaho 83686
Nampa, Idaho 83686
Post Falls, Idaho 83854
Sandpoint, Idaho 83864
Twin Falls, Idaho 83301
Aurora, Illinois 60504
Bloomington, Illinois 61704
Canton, Illinois 61520
Carbondale, Illinois 62902
Carterville, Illinois 62918
Carthage, Illinois 62321
Centralia, Illinois 62801
Chicago, Illinois 60611
Chicago, Illinois 60612
Site Public Contact
312-864-5204
Chicago, Illinois 60612
Chicago, Illinois 60612
Site Public Contact
312-355-3046
Chicago, Illinois 60637
Danville, Illinois 61832
Decatur, Illinois 62526
Decatur, Illinois 62526
Dixon, Illinois 61021
Site Public Contact
815-285-7800
Effingham, Illinois 62401
Effingham, Illinois 62401
Eureka, Illinois 61530
Evanston, Illinois 60201
Site Public Contact
847-570-2109
Galesburg, Illinois 61401
Galesburg, Illinois 61401
Site Public Contact
309-344-2831
Geneva, Illinois 60134
Glenview, Illinois 60026
Site Public Contact
847-570-2109
Highland Park, Illinois 60035
Site Public Contact
847-570-2109
Hinsdale, Illinois 60521
Site Public Contact
630-856-6757
Kewanee, Illinois 61443
Lake Forest, Illinois 60045
Macomb, Illinois 61455
Mattoon, Illinois 61938
Maywood, Illinois 60153
Site Public Contact
708-226-4357
Melrose Park, Illinois 60160
Site Public Contact
708-450-4554
Mount Vernon, Illinois 62864
Site Public Contact
618-242-4600
New Lenox, Illinois 60451
O'Fallon, Illinois 62269
Orland Park, Illinois 60462
Ottawa, Illinois 61350
Pekin, Illinois 61554
Peoria, Illinois 61615
Peoria, Illinois 61636
Peru, Illinois 61354
Peru, Illinois 61354
Site Public Contact
815-664-4141
Princeton, Illinois 61356
Springfield, Illinois 62702
Site Public Contact
217-545-7929
Springfield, Illinois 62702
Site Public Contact
800-444-7541
Springfield, Illinois 62781
Site Public Contact
217-788-3528
Urbana, Illinois 61801
Urbana, Illinois 61801
Warrenville, Illinois 60555
Yorkville, Illinois 60560
Zion, Illinois 60099
Fort Wayne, Indiana 46845
Site Public Contact
877-784-4673
Indianapolis, Indiana 46202
Indianapolis, Indiana 46237
Site Public Contact
317-528-7060
Indianapolis, Indiana 46260
Lafayette, Indiana 47905
Michigan City, Indiana 46360
Mooresville, Indiana 46158
Site Public Contact
317-834-3603
Richmond, Indiana 47374
South Bend, Indiana 46601
Site Public Contact
800-284-7370
Terre Haute, Indiana 47804
Site Public Contact
812-238-7394
Clive, Iowa 50325
Clive, Iowa 50325
Council Bluffs, Iowa 51503
Creston, Iowa 50801
Des Moines, Iowa 50314
Des Moines, Iowa 50314
Iowa City, Iowa 52242
Site Public Contact
800-237-1225
West Des Moines, Iowa 50266
Hays, Kansas 67601
Site Public Contact
785-623-5774
Kansas City, Kansas 66160
Lawrence, Kansas 66044
Olathe, Kansas 66061
Overland Park, Kansas 66210
Overland Park, Kansas 66211
Pittsburg, Kansas 66762
Salina, Kansas 67401
Topeka, Kansas 66606
Site Public Contact
785-270-4939
Topeka, Kansas 66606
Site Public Contact
785-295-8000
Westwood, Kansas 66205
Bardstown, Kentucky 40004
Corbin, Kentucky 40701
Site Public Contact
859-523-1934
Corbin, Kentucky 40701
Edgewood, Kentucky 41017
Lexington, Kentucky 40503
Site Public Contact
859-260-6425
Lexington, Kentucky 40504
Lexington, Kentucky 40509
London, Kentucky 40741
Louisville, Kentucky 40202
Louisville, Kentucky 40202
Louisville, Kentucky 40207
Louisville, Kentucky 40207
Site Public Contact
502-629-3465
Louisville, Kentucky 40215
Louisville, Kentucky 40241
Louisville, Kentucky 40245
Madisonville, Kentucky 42431
Site Public Contact
800-733-2312
Paducah, Kentucky 42003
Site Public Contact
270-575-2928
Shepherdsville, Kentucky 40165
Baton Rouge, Louisiana 70809
Baton Rouge, Louisiana 70809
Baton Rouge, Louisiana 70816
Baton Rouge, Louisiana 70836
Covington, Louisiana 70433
New Orleans, Louisiana 70112
Site Public Contact
504-988-6121
New Orleans, Louisiana 70115
New Orleans, Louisiana 70121
Bangor, Maine 04401
Site Public Contact
207-973-4274
Brewer, Maine 04412
Site Public Contact
800-987-3005
Scarborough, Maine 04074
Baltimore, Maryland 21204
Site Public Contact
443-849-3706
Baltimore, Maryland 21244
Site Public Contact
301-816-7218
Baltimore, Maryland 21287
Easton, Maryland 21601
Gaithersburg, Maryland 20879
Site Public Contact
301-816-7218
Kensington, Maryland 20895
Site Public Contact
301-816-7218
Largo, Maryland 20774
Site Public Contact
301-816-7446
Burlington, Massachusetts 01805
Peabody, Massachusetts 01960
Springfield, Massachusetts 01199
Worcester, Massachusetts 01605
Site Public Contact
508-856-6265
Ann Arbor, Michigan 48109
Site Public Contact
800-865-1125
Battle Creek, Michigan 49017
Brownstown, Michigan 48183
Clinton Township, Michigan 48038
Dearborn, Michigan 48126
Detroit, Michigan 48201
Detroit, Michigan 48202
Farmington Hills, Michigan 48334
Grand Rapids, Michigan 49503
Grand Rapids, Michigan 49503
Grand Rapids, Michigan 49503
Jackson, Michigan 49201
Kalamazoo, Michigan 49007
Kalamazoo, Michigan 49007
Kalamazoo, Michigan 49048
Muskegon, Michigan 49444
Niles, Michigan 49120
Site Public Contact
616-391-1230
Norton Shores, Michigan 49444
Novi, Michigan 48377
Reed City, Michigan 49677
Saint Joseph, Michigan 49085
Saint Joseph, Michigan 49085
Shelby, Michigan 48315
Traverse City, Michigan 49684
West Bloomfield, Michigan 48322
Wyoming, Michigan 49519
Bemidji, Minnesota 56601
Burnsville, Minnesota 55337
Burnsville, Minnesota 55337
Cambridge, Minnesota 55008
Coon Rapids, Minnesota 55433
Edina, Minnesota 55435
Fridley, Minnesota 55432
Maple Grove, Minnesota 55369
Maplewood, Minnesota 55109
Maplewood, Minnesota 55109
Minneapolis, Minnesota 55407
Minneapolis, Minnesota 55415
Minneapolis, Minnesota 55454
Monticello, Minnesota 55362
New Ulm, Minnesota 56073
Princeton, Minnesota 55371
Robbinsdale, Minnesota 55422
Saint Louis Park, Minnesota 55416
Saint Paul, Minnesota 55101
Saint Paul, Minnesota 55102
Shakopee, Minnesota 55379
Stillwater, Minnesota 55082
Waconia, Minnesota 55387
Willmar, Minnesota 56201
Woodbury, Minnesota 55125
Wyoming, Minnesota 55092
Jackson, Mississippi 39216
Site Public Contact
601-815-6700
Ballwin, Missouri 63011
Site Public Contact
314-251-7058
Cape Girardeau, Missouri 63703
Cape Girardeau, Missouri 63703
Site Public Contact
573-651-5550
Farmington, Missouri 63640
Site Public Contact
314-996-5569
Jefferson City, Missouri 65109
Joplin, Missouri 64804
Joplin, Missouri 64804
Kansas City, Missouri 64108
Site Public Contact
816-404-4375
North Kansas City, Missouri 64116
Rolla, Missouri 65401
Rolla, Missouri 65401
Site Public Contact
573-458-6379
Saint Joseph, Missouri 64506
Saint Louis, Missouri 63109
Site Public Contact
314-353-1870
Saint Louis, Missouri 63110
Saint Louis, Missouri 63131
Site Public Contact
314-996-5569
Saint Louis, Missouri 63141
Site Public Contact
314-251-7066
Sainte Genevieve, Missouri 63670
Site Public Contact
314-996-5569
Springfield, Missouri 65804
Site Public Contact
417-269-4520
Springfield, Missouri 65807
Site Public Contact
417-269-4520
Sullivan, Missouri 63080
Site Public Contact
314-996-5569
Sunset Hills, Missouri 63127
Site Public Contact
314-996-5569
Washington, Missouri 63090
Site Public Contact
636-390-1600
Anaconda, Montana 59711
Billings, Montana 59101
Billings, Montana 59101
Billings, Montana 59102
Site Public Contact
800-648-6274
Bozeman, Montana 59715
Great Falls, Montana 59405
Great Falls, Montana 59405
Kalispell, Montana 59901
Missoula, Montana 59802
Missoula, Montana 59804
Grand Island, Nebraska 68803
Kearney, Nebraska 68847
Lincoln, Nebraska 68510
Omaha, Nebraska 68114
Site Public Contact
402-354-5144
Omaha, Nebraska 68122
Omaha, Nebraska 68124
Omaha, Nebraska 68130
Omaha, Nebraska 68131
Omaha, Nebraska 68198
Papillion, Nebraska 68046
Carson City, Nevada 89703
Henderson, Nevada 89052
Henderson, Nevada 89052
Henderson, Nevada 89052
Henderson, Nevada 89052
Henderson, Nevada 89052
Henderson, Nevada 89074
Henderson, Nevada 89074
Henderson, Nevada 89074
Henderson, Nevada 89074
Las Vegas, Nevada 89102
Las Vegas, Nevada 89102
Las Vegas, Nevada 89102
Las Vegas, Nevada 89103
Las Vegas, Nevada 89106
Las Vegas, Nevada 89109
Las Vegas, Nevada 89109
Las Vegas, Nevada 89113
Las Vegas, Nevada 89128
Las Vegas, Nevada 89128
Las Vegas, Nevada 89128
Las Vegas, Nevada 89128
Las Vegas, Nevada 89128
Las Vegas, Nevada 89128
Las Vegas, Nevada 89135
Las Vegas, Nevada 89144
Las Vegas, Nevada 89144
Las Vegas, Nevada 89144
Las Vegas, Nevada 89148-2405
Las Vegas, Nevada 89148
Las Vegas, Nevada 89148
Las Vegas, Nevada 89148
Las Vegas, Nevada 89148
Las Vegas, Nevada 89169
Las Vegas, Nevada 89169
Las Vegas, Nevada 89169
Pahrump, Nevada 89048
Reno, Nevada 89502
Reno, Nevada 89503
Reno, Nevada 89509
Lebanon, New Hampshire 03756
Nashua, New Hampshire 03063
Basking Ridge, New Jersey 07920
Site Public Contact
212-639-7592
Cape May Court House, New Jersey 08210
Site Public Contact
888-369-2427
Egg Harbor Township, New Jersey 08234
Site Public Contact
609-748-7200
Hackensack, New Jersey 07601
Site Public Contact
201-996-2879
Lakewood, New Jersey 08701
Long Branch, New Jersey 07740
Middletown, New Jersey 07748
Site Public Contact
212-639-7592
Montvale, New Jersey 07645
Site Public Contact
212-639-7592
New Brunswick, New Jersey 08903
Site Public Contact
732-235-7356
Paramus, New Jersey 07652
Site Public Contact
201-634-5792
Ridgewood, New Jersey 07450
Ridgewood, New Jersey 07450
Somerville, New Jersey 08876
Wayne, New Jersey 07470
Westwood, New Jersey 07675
Albuquerque, New Mexico 87102
Albuquerque, New Mexico 87106
Bronx, New York 10461
Bronx, New York 10461
Bronx, New York 10467
Buffalo, New York 14263
Commack, New York 11725
Site Public Contact
212-639-7592
Harrison, New York 10604
Site Public Contact
212-639-7592
New York, New York 10011
New York, New York 10016
New York, New York 10029
New York, New York 10065
Site Public Contact
212-639-7592
Rochester, New York 14642
Site Public Contact
585-275-5830
Syracuse, New York 13210
Site Public Contact
315-464-5476
Syracuse, New York 13215
Site Public Contact
315-464-5476
Uniondale, New York 11553
Site Public Contact
212-639-7592
Asheboro, North Carolina 27203
Asheville, North Carolina 28816
Burlington, North Carolina 27215
Chapel Hill, North Carolina 27599
Charlotte, North Carolina 28203
Site Public Contact
800-804-9376
Charlotte, North Carolina 28204
Clinton, North Carolina 28328
Concord, North Carolina 28025
Site Public Contact
800-804-9376
Durham, North Carolina 27710
Site Public Contact
888-275-3853
Goldsboro, North Carolina 27534
Greensboro, North Carolina 27403
Hendersonville, North Carolina 28791
Huntersville, North Carolina 28078
Jacksonville, North Carolina 28546
Kernersville, North Carolina 27284
Mebane, North Carolina 27302
Mount Airy, North Carolina 27030
Raleigh, North Carolina 27609
Site Public Contact
919-862-5400
Reidsville, North Carolina 27320
Statesville, North Carolina 28625
Thomasville, North Carolina 27360
Wilkesboro, North Carolina 28659
Wilmington, North Carolina 28401
Site Public Contact
910-342-3000
Winston-Salem, North Carolina 27103
Bismarck, North Dakota 58501
Fargo, North Dakota 58122
Fargo, North Dakota 58122
Alliance, Ohio 44601
Site Public Contact
330-363-1250
Beachwood, Ohio 44122
Beavercreek, Ohio 45431
Belpre, Ohio 45714
Boardman, Ohio 44512
Canton, Ohio 44710
Centerville, Ohio 45459
Centerville, Ohio 45459
Chardon, Ohio 44024
Chillicothe, Ohio 45601
Cincinnati, Ohio 45219
Cincinnati, Ohio 45220
Cincinnati, Ohio 45236
Cincinnati, Ohio 45242
Cincinnati, Ohio 45247
Cincinnati, Ohio 45255
Cleveland, Ohio 44106
Cleveland, Ohio 44109
Cleveland, Ohio 44111
Cleveland, Ohio 44195
Columbus, Ohio 43210
Columbus, Ohio 43213
Columbus, Ohio 43214
Columbus, Ohio 43214
Columbus, Ohio 43215
Columbus, Ohio 43219
Columbus, Ohio 43222
Columbus, Ohio 43228
Dayton, Ohio 45405
Site Public Contact
937-395-8115
Dayton, Ohio 45409
Dayton, Ohio 45415
Dayton, Ohio 45415
Delaware, Ohio 43015
Delaware, Ohio 43015
Dublin, Ohio 43016
Elyria, Ohio 44035
Findlay, Ohio 45840
Findlay, Ohio 45840
Findlay, Ohio 45840
Franklin, Ohio 45005-1066
Franklin, Ohio 45005
Greenville, Ohio 45331
Greenville, Ohio 45331
Grove City, Ohio 43123
Kettering, Ohio 45409
Kettering, Ohio 45429
Lancaster, Ohio 43130
Mansfield, Ohio 44903
Marietta, Ohio 45750
Marion, Ohio 43302
Mayfield Heights, Ohio 44124
Mentor, Ohio 44060
Middleburg Heights, Ohio 44130
Mount Vernon, Ohio 43050
Newark, Ohio 43055
Newark, Ohio 43055
Portsmouth, Ohio 45662
Sandusky, Ohio 44870
Sylvania, Ohio 43560
Site Public Contact
419-824-1842
Toledo, Ohio 43606
Site Public Contact
419-824-1842
Troy, Ohio 45373
Troy, Ohio 45373
Wadsworth, Ohio 44281
Warren, Ohio 44484
West Chester, Ohio 45069
Westerville, Ohio 43081
Westlake, Ohio 44145
Westlake, Ohio 44145
Youngstown, Ohio 44501
Zanesville, Ohio 43701
Oklahoma City, Oklahoma 73104
Oklahoma City, Oklahoma 73120
Site Public Contact
405-752-3402
Tulsa, Oklahoma 74146
Site Public Contact
918-505-3200
Baker City, Oregon 97814
Bend, Oregon 97701
Clackamas, Oregon 97015
Clackamas, Oregon 97015
Coos Bay, Oregon 97420
Gresham, Oregon 97030
Site Public Contact
503-413-2150
Newberg, Oregon 97132
Ontario, Oregon 97914
Portland, Oregon 97210
Portland, Oregon 97213
Portland, Oregon 97225
Tualatin, Oregon 97062
Site Public Contact
503-413-1742
Bethlehem, Pennsylvania 18015
Site Public Contact
484-503-4151
Bryn Mawr, Pennsylvania 19010
Chadds Ford, Pennsylvania 19317
Collegeville, Pennsylvania 19426
Danville, Pennsylvania 17822
Exton, Pennsylvania 19341
Harrisburg, Pennsylvania 17109
Hazleton, Pennsylvania 18201
Jefferson Hills, Pennsylvania 15025
Lancaster, Pennsylvania 17601
Site Public Contact
717-544-0511
Lancaster, Pennsylvania 17602
Site Public Contact
717-544-5511
Lewisburg, Pennsylvania 17837
Lewistown, Pennsylvania 17044
Media, Pennsylvania 19063
Monroeville, Pennsylvania 15146
Site Public Contact
412-858-7746
New Castle, Pennsylvania 16105
Paoli, Pennsylvania 19301
Philadelphia, Pennsylvania 19104
Site Public Contact
800-474-9892
Philadelphia, Pennsylvania 19107
Site Public Contact
215-955-6084
Pittsburgh, Pennsylvania 15212
Site Public Contact
877-284-2000
Pittsburgh, Pennsylvania 15224
Site Public Contact
412-578-5000
Pittsburgh, Pennsylvania 15232
Site Public Contact
412-647-8073
Pottsville, Pennsylvania 17901
Scranton, Pennsylvania 18510
Selinsgrove, Pennsylvania 17870
State College, Pennsylvania 16801
West Chester, Pennsylvania 19380
Site Public Contact
610-431-5297
West Reading, Pennsylvania 19611
Site Public Contact
610-988-9323
Wexford, Pennsylvania 15090
Wilkes-Barre, Pennsylvania 18711
Willow Grove, Pennsylvania 19090
Site Public Contact
215-481-2402
Wynnewood, Pennsylvania 19096
Providence, Rhode Island 02905
Site Public Contact
401-274-1122
Anderson, South Carolina 29621
Charleston, South Carolina 29425
Greenville, South Carolina 29601
Greenville, South Carolina 29607
Sioux Falls, South Dakota 57104
Sioux Falls, South Dakota 57105
Sioux Falls, South Dakota 57117-5134
Bristol, Tennessee 37620
Franklin, Tennessee 37067
Site Public Contact
800-811-8480
Kingsport, Tennessee 37660
Kingsport, Tennessee 37660
Knoxville, Tennessee 37916
Site Public Contact
865-331-1812
Knoxville, Tennessee 37932
Site Public Contact
865-331-1812
Nashville, Tennessee 37204
Site Public Contact
800-811-8480
Nashville, Tennessee 37232
Site Public Contact
800-811-8480
Oak Ridge, Tennessee 37830
Site Public Contact
865-331-1812
Bryan, Texas 77802
Dallas, Texas 75235
Dallas, Texas 75390
Fort Worth, Texas 76104
Houston, Texas 77030
Houston, Texas 77030
Site Public Contact
713-873-2000
Houston, Texas 77030
Site Public Contact
713-790-2700
Houston, Texas 77070
Sugar Land, Texas 77479
Site Public Contact
281-242-2873
Bristol, Virginia 24201
Burke, Virginia 22015
Charlottesville, Virginia 22908
Falls Church, Virginia 22042
McLean, Virginia 22102
Site Public Contact
240-632-4284
Norton, Virginia 24273
Richmond, Virginia 23298
Roanoke, Virginia 24016
Site Public Contact
540-985-8510
Aberdeen, Washington 98520
Bellevue, Washington 98004
Bellingham, Washington 98225
Bremerton, Washington 98310
Bremerton, Washington 98310
Burien, Washington 98166
Centralia, Washington 98531
Edmonds, Washington 98026
Enumclaw, Washington 98022
Everett, Washington 98201
Federal Way, Washington 98003
Issaquah, Washington 98029
Kennewick, Washington 99336
Lacey, Washington 98503
Lakewood, Washington 98499
Longview, Washington 98632
Port Townsend, Washington 98368
Site Public Contact
360-344-3091
Poulsbo, Washington 98370
Renton, Washington 98055
Seattle, Washington 98104
Seattle, Washington 98107
Seattle, Washington 98122-4307
Seattle, Washington 98122-5711
Shelton, Washington 98584
Tacoma, Washington 98405
Tacoma, Washington 98405
Vancouver, Washington 98664
Vancouver, Washington 98686
Site Public Contact
503-413-2150
Walla Walla, Washington 99362
Yelm, Washington 98597
Bridgeport, West Virginia 26330
Charleston, West Virginia 25304
Site Public Contact
304-388-9944
Martinsburg, West Virginia 25401
Morgantown, West Virginia 26505
Site Public Contact
304-598-6560
Morgantown, West Virginia 26506
Parkersburg, West Virginia 26101
Burlington, Wisconsin 53105
Chippewa Falls, Wisconsin 54729
Eau Claire, Wisconsin 54701
Fond Du Lac, Wisconsin 54937
Germantown, Wisconsin 53022
Grafton, Wisconsin 53024
Green Bay, Wisconsin 54301
Green Bay, Wisconsin 54303
Green Bay, Wisconsin 54311
Kenosha, Wisconsin 53142
Ladysmith, Wisconsin 54848
Madison, Wisconsin 53792
Site Public Contact
800-622-8922
Marinette, Wisconsin 54143
Marshfield, Wisconsin 54449
Milwaukee, Wisconsin 53209
Milwaukee, Wisconsin 53215
Milwaukee, Wisconsin 53226
Site Public Contact
414-805-3666
Milwaukee, Wisconsin 53233
Minocqua, Wisconsin 54548
New Richmond, Wisconsin 54017
Oconto Falls, Wisconsin 54154
Oshkosh, Wisconsin 54904
Racine, Wisconsin 53406
Rice Lake, Wisconsin 54868
Sheboygan, Wisconsin 53081
Stevens Point, Wisconsin 54482
Sturgeon Bay, Wisconsin 54235-1495
Summit, Wisconsin 53066
Two Rivers, Wisconsin 54241
Wausau, Wisconsin 54401
Wauwatosa, Wisconsin 53226
West Allis, Wisconsin 53227
Weston, Wisconsin 54476
Wisconsin Rapids, Wisconsin 54494
Cheyenne, Wyoming 82001
Cody, Wyoming 82414
Sheridan, Wyoming 82801
Bayamon, Puerto Rico 00959-5060
Site Public Contact
787-395-7085
Caguas, Puerto Rico 00726
Site Public Contact
787-653-3434
Manati, Puerto Rico 00674
Site Public Contact
787-621-4397
Ponce, Puerto Rico 00716
Site Public Contact
787-848-0606
San Juan, Puerto Rico 00917
Site Public Contact
787-274-3387
San Juan, Puerto Rico 00927
San Juan, Puerto Rico 00936
Site Public Contact
787-763-1296
More Details
- NCT ID
- NCT02839707
- Status
- Recruiting
- Sponsor
- National Cancer Institute (NCI)
Detailed Description
PRIMARY OBJECTIVES: I. Estimate the probability of a dose limiting toxicity (DLT) following cycle 1 of experimental regimens (pegylated liposomal doxorubicin hydrochloride [pegylated liposomal doxorubicin] [PLD] and atezolizumab and PLD/bevacizumab and atezolizumab). (Safety lead-in) II. Estimate and compare the hazard of first progression or death (progression free survival [PFS]) of each experimental regimen relative to the reference regimen, PLD and bevacizumab. (Phase II study) III. Estimate and compare the hazard of death and the hazard of first progression or death (PFS) of each experimental regimen relative to the reference regimen. (Phase III) SECONDARY OBJECTIVES: I. Estimate and compare the probabilities of response rate (objective response rate [ORR], either partial or complete response) defined by Response Evaluation Criteria in Solid Tumors (RECIST) version (v)1.1 criteria on each study regimen. (Phase II study) II. Estimate the frequency and severity of adverse events as classified and graded with Common Terminology Criteria for Adverse Events (CTCAE) in those patients who initiate their randomly assigned study treatment. (Phase II study) III. Estimate and compare ORR in each treatment group. (Phase III study) IV. Estimate the frequency and severity of adverse events in those patients who initiate their randomly assigned study treatment. (Phase III study) V. Estimate and compare mean patient reported outcome scores (PROs) as measured by National Comprehensive Cancer Network (NCCN)-Functional Assessment of Cancer Therapy (FACT) ovarian symptom index (NFOSI)-18 disease-related symptoms (DRS). (Phase III study) VI. Estimate and compare the treatment groups on the basis of the PROs: treatment side effects (TSE), function/well-being (FWB), fatigue (Functional Assessment of Chronic Illness Therapy [FACIT]-fatigue subscale) and abdominal discomfort (FACT/Gynecologic Oncology Group [GOG]-abdominal discomfort [AD] subscale). (Phase III study) TRANSLATIONAL SCIENCE OBJECTIVES: I. To determine whether biomarker levels in pre-treatment tissue, and pre- or on-treatment peripheral blood, and stool specimens are associated with ORR, PFS and/or overall survival (OS). II. To determine whether changes in quantitative biomarker parameters after the first 6 and 12 weeks of therapy predict ORR, PFS and/or OS. OUTLINE: Patients will be randomized to 1 of 3 arms. ARM I: Patients receive pegylated liposomal doxorubicin hydrochloride intravenously (IV) over 60 minutes on day 1 and atezolizumab IV over 30-60 minutes on days 1 and 15. ARM II: Patients receive pegylated liposomal doxorubicin hydrochloride IV over 60 minutes on day 1, bevacizumab IV over 30-90 minutes on days 1 and 15, and atezolizumab IV over 30-60 minutes on days 1 and 15. ARM III: Patients receive pegylated liposomal doxorubicin hydrochloride IV over 60 minutes on day 1 and bevacizumab IV over 30-90 minutes on days 1 and 15. In all arms, cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. After completion of study treatment, patients are followed up every 3 months for up to 2 years, and then every 6 months for up to 3 years.